Bicycle Therapeutics (BCYC) risk factors, FY2025 10-K

Other

1. 01Summary of Selected Risk Factors

Risks Related to Our Financial Position and Need for Additional Capital

1. 02We have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future, and we may never achieve or maintain profitability
2. 03and any collaborators may never succeed in these activities and, even if we do, or any collaborators do, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis
3. 04Our limited operating history may make it difficult for holders of our ADSs or ordinary shares to evaluate the success of our business to date and to assess our future viability
4. 05We may need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts
5. 06Raising additional capital may cause dilution to our existing shareholders or holders of our ADSs, restrict our operations or cause us to relinquish valuable rights

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

1. 07Our future success will depend heavily on the success of our internal development programs and of product candidates from our BDC and BRC programs62% rewritten
2. 08We are at an early stage in our development efforts, and our product candidates and those of our collaborators represent a new category of medicines and may be subject to heightened regulatory scrutiny until they are established as a therapeutic modality
3. 09If we are unsuccessful in our development efforts, we may not be able to advance the development of our product candidates, commercialize products, raise capital, expand our business or continue our operations
4. 10We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates
5. 11Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials20% rewritten
6. 12Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics could harm our drug development strategy
7. 13We may be delayed or may not be successful in our efforts to identify or discover additional product candidates
8. 14We may expend our limited resources to pursue a particular development strategy, product candidate or indication and fail to capitalize on strategies, product candidates or indications that may be more profitable or for which there is a greater likelihood of success98% rewritten
9. 15We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process
10. 16Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not mean that we will be successful in obtaining marketing approval of our current and future product candidates in other jurisdictions62% rewritten
11. 17Changes in the regulatory landscape, policies, or processes, as well as disruptions at the FDA and other government agencies caused by layoffs, changes in personnel, funding shortages or global health concerns could negatively impact our businessNew

Risks Related to Commercialization of Our Product Candidates and Other Regulatory Compliance Matters

1. 18Any delay in obtaining or failure to obtain required approvals could negatively impact our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact the price of our ADSs
2. 19The market opportunities for any current or future product candidate we develop, if and when approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small
3. 20The life sciences industry is highly competitive. We are currently developing therapeutics that will compete, if approved, with other products and therapies that currently exist, are being developed or will in the future be developed, some of which we may not currently be aware
4. 21The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, payors and others in the medical community
5. 22If the market opportunities for our product candidates are smaller than we believe they are, our product revenues may be adversely affected and our business may suffer
6. 23The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for any of our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue72% rewritten
7. 24Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the approved drugs for a particular indicationNew
8. 25If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed
9. 26We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other health care laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties
10. 27Healthcare legislative reform measures may have a negative impact on our business and results of operations80% rewritten
11. 28In addition to data privacy and security laws, we are also bound by other contractual and industry obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful93% rewritten
12. 29misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequencesNew
13. 30If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business31% rewritten
14. 31efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctionsNew

Risks Related to Our Business and Our International Operations

1. 32As a company with operations outside of the United States, we are subject to economic, political, regulatory and other risks associated with international operations77% rewritten
2. 33International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospectsNew
3. 34during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security programNew
4. 35Social media platforms and artificial intelligence-based platforms present new risks and challenges to our business39% rewritten
5. 36Exchange rate fluctuations may materially affect our results of operations and financial condition

Risks Related to Our Dependence on Third Parties

1. 37For certain products candidates, we depend, or may depend, on development and commercialization collaboration partners to develop, conduct clinical trials of, and, if approved, sell product candidates67% rewritten
2. 38From time to time, we may also explore partnership opportunities for certain of our product candidates, such as BT7480. However there can be no assurance that we will be able to do so, or that such relationships, if established, will be successful or on favorable termsNew
3. 39If conflicts arise with our development and commercialization collaborators or licensors, they may act in their own self-interest, which may be adverse to the interests of our company
4. 40For example, we were previously involved in litigation with Pepscan Systems B.V., and its affiliates, or Pepscan, related to a non-exclusive patent license agreement that our subsidiary, BicycleRD Limited, or BicycleRD, entered into with Pepscan in 200952% rewritten
5. 41We may be delayed if we need to change the manufacturing process used by a third party. Further, if we change an approved manufacturing process, then we may be delayed if the FDA or a comparable foreign authority needs to review the new manufacturing process before it may be used
6. 42Our future product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP requirements that might be capable of manufacturing for us
7. 43Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed

Risks Related to Our Intellectual Property

1. 44Issued patents covering our products and product candidates could be found invalid or unenforceable if challenged in court or in administrative proceedings. We may not be able to protect our trade secrets in court62% rewritten
2. 45protection may materially harm our intellectual property estate, which would impair our ability to establish competitive barriers to entry in the form of intellectual property protectionsNew
3. 46We may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property
4. 47Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
5. 48If we do not obtain patent term extension and data exclusivity for our products and product candidates, our business may be materially harmed
6. 49Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products and product candidates53% rewritten
7. 50We may not be able to protect our intellectual property rights throughout the world
8. 51If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates
9. 52We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property
10. 53We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful
11. 54If we fail to comply with our obligations under any future intellectual property licenses with third parties, we could lose license rights that are important to our business
12. 55If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected69% rewritten
13. 56trademark registration proceedings, we may receive objections. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such objectionsNew

Risks Related to Employee Matters and Managing Growth

1. 57Our recent workforce reductions were undertaken to significantly reduce our ongoing operating expenses, but they may not result in our intended outcomes and may yield unintended consequences and additional costsNew
2. 58Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel49% rewritten
3. 59Our employees, independent contractors, consultants, collaborators and CROs may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation
4. 60We may encounter difficulties in managing our growth, which could disrupt our operationsNew

Risks Related to Ownership of Our Securities

1. 61The market price of our ADSs is highly volatile, and holders of our ADSs may not be able to resell their ADSs at or above the price at which they purchased their ADSs27% rewritten
2. 62The dual class structure of our shares may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions
3. 63Substantial future sales or issuances of shares of our ordinary shares or ADSs or other equity-related securities could adversely affect the price of our ADSs and dilute shareholders32% rewritten
4. 64Our existing shareholders may consult with our management and have various impacts on our business affairs
5. 65Because we do not anticipate paying any cash dividends on our ADSs in the foreseeable future, capital appreciation, if any, will be the sole source of gains for holders of our ADSs, and they may never receive a return on their investment

Risks Related to Our Incorporation Under the Laws of England and Wales

1. 66Claims of U.S. civil liabilities may not be enforceable against us42% rewritten
2. 67We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable U.K. tax legislation
3. 68Future changes to tax laws could materially adversely affect our company and reduce net returns to our shareholders55% rewritten
4. 69Tax authorities may disagree with our positions and conclusions regarding certain tax positions, or may apply existing rules in an unforeseen manner, resulting in unanticipated costs, taxes or non-realization of expected benefits
5. 70Provisions in the U.K. City Code on Takeovers and Mergers that may have anti-takeover effects do not apply to us32% rewritten
6. 71The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation

General Risks

1. 72Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
2. 73We could be subject to securities class action litigation
3. 74If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our ADS price and trading volume could decline